ICLE 2018: International Conference on Lymphocyte Engineering 2018
September 13 - 15, 2018 - Madrid ESKenes Group
reg_icle18@kenes.com
Phone:359 2 8082110
The inaugural International Conference on Lymphocyte Engineering (ICLE 2018), will take place in Madrid, on 13-15 September 2018. The theme of ICLE is “Advancing immuno-gene therapy across diseases”, emphasising the need for combined efforts of a dedicated community to realize the full promise of lymphocyte engineering. Programme highlights include: • Lymphocyte engineering for the treatment of Hematological malignancies • Lymphocyte engineering for the treatment of Solid tumors • Genome editing for allogeneic ACT • Safety switches & controlled expression • Engineering HSC, NK, NKT and γδ T cells • Target & receptor discovery • Lymphocyte engineering for the treatment of HIV • Optimizing receptor and vector design • Non viral vectors and transposons Whether you are a scientist, clinical researcher, part of a start-up or an established industry company, ICLE 2018 is your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about this innovative treatment modality as you. Abstract Submission Deadline: 23 May 2018 Early Registration Deadline: 19 June 2018 For Support Opportunities please visit: http://lymphocyte.kenes.com/2018/sponsorship-exhibition/sponsorship-exhibition Chair: Adi Barzel, PhD, Senior Lecturer at Dept. of Biochemistry & Molecular Biology, George S. Wise Faculty of Life Sciences, Tel Aviv University; President-Elect of the Israeli Society of Gene and Cell Therapy, Co-Founder of LogicBio Therapeutics Advisory board: • Malcolm Brenner, USA • Paula Cannon, USA • Cyrille Cohen, Israel • Zelig Eshhar, Israel • Dinorah Friedmann-Morvinski, Israel • Stephen Gottschalk, USA • Aya Jakobovits, USA • Carl June, USA • Bruce Levine, USA • Marcela Maus, USA • Dan Peer, Israel • Mattew Porteus, USA • Daniel Powell, USA • Barbara Savoldo, USA